Journal
JOURNAL OF NUCLEAR MEDICINE
Volume 56, Issue 5, Pages 668-674Publisher
SOC NUCLEAR MEDICINE INC
DOI: 10.2967/jnumed.115.154153
Keywords
PSMA ligand; PET/CT; hybrid imaging; prostate cancer; biochemical recurrence
Funding
- European Union [294582]
- Deutsche Forschungsgemeinschaft, Bonn, Germany [SFB 824, DFG Sonderforschungsbereich 824]
Ask authors/readers for more resources
The expression of prostate-specific membrane antigen (PSMA) is increased in prostate cancer. Recently, Ga-68-PSMA (Glu-NH-CO-NH-Lys-(Ahx)-[Ga-68(HBED-CC)]) was developed as a PSMA ligand. The aim of this study was to investigate the detection rate of Ga-68-PSMA PET/CT in patients with biochemical recurrence after radical prostatectomy. Methods: Two hundred forty-eight of 393 patients were evaluable for a retrospective analysis. Median prostate-specific antigen (PSA) level was 1.99 ng/mL (range, 0.2-59.4 ng/mL). All patients underwent contrast-enhanced PET/CT after injection of 155 +/- 27 MBq of Ga-68-PSMA ligand. The detection rates were correlated with PSA level and PSA kinetics. The influence of anti-hormonal treatment, primary Gleason score, and contribution of PET and morphologic imaging to the final diagnosis were assessed. Results: Two hundred twenty-two (89.5%) patients showed pathologic findings in Ga-68-PSMA ligand PET/CT. The detection rates were 96.8%, 93.0%, 72.7%, and 57.9% for PSA levels of >= 2, 1 to <2, 0.5 to <1, and 0.2 to <0.5 ng/mL, respectively. Whereas detection rates increased with a higher PSA velocity (81.8%, 82.4%, 92.1%, and 100% in <1, 1 to <2, 2 to <5, and >= 5 ng/mL/y, respectively), no significant association could be found for PSA doubling time (82.7%, 96.2%, and 90.7% in >6, 4-6, and <4 mo, respectively). Ga-68-PSMA ligand PET (as compared with CT) exclusively provided pathologic findings in 81 (32.7%) patients. In 61 (24.6%) patients, it exclusively identified additional involved regions. In higher Gleason score (<= 7 vs. >= 8), detection efficacy was significantly increased (P = 0.0190). No significant difference in detection efficacy was present regarding antiandrogen therapy (P = 0.0783). Conclusion: Hybrid Ga-68-PSMA ligand PET/CT shows substantially higher detection rates than reported for other imaging modalities. Most importantly, it reveals a high number of positive findings in the clinically important range of low PSA values (<0.5 ng/mL), which in many cases can substantially influence the further clinical management.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available